Research programme: gene therapies - iVeena Delivery Systems

Drug Profile

Research programme: gene therapies - iVeena Delivery Systems

Alternative Names: IVMED 50; IVMED 55; IVMED 60

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator iVeena Delivery Systems
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetic retinopathy; Wet age-related macular degeneration

Most Recent Events

  • 17 Nov 2017 Preclinical trials in Diabetic retinopathy in USA (IV) before November 2017 (iVeena delivery systems pipeline, November 2017)
  • 17 Nov 2017 Preclinical trials in Wet age-related macular degeneration in USA (Ophthalmic) before November 2017 (iVeena delivery systems pipeline, November 2017)
  • 17 Nov 2017 Preclinical trials in Wet age-related macular degeneration in USA (Parenteral) before November 2017 (iVeena delivery systems pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top